Shots:

• Oncoheroes to get IP rights with an exclusive right to research- develop- sell and sublicense Boehringer’s Volasertib. Oncoheroes will further develop & commercialize volasertib for pediatric cancer indications
• The license agreement allows Boehringer to continue the clinical development of volasertib to benefit pediatric patients with cancer
• Volasertib is a Polo-like-kinase 1 inhibitor with strong clinical data supporting its development for rhabdomyosarcoma and a few other pediatric cancer indications. Boehringer developed Volasertib for a specific form of leukemia but it discontinued the clinical activities following the failure of P-III study in adults

Click here to­ read full press release/ article | Ref: PRNewswire | Image: PharmaNews